Immunyx Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $30K

  • Investors
  • 7

Immunyx General Information

Description

Developer of the targeted neutrophil nanoparticle platform intended to treat neutrophils in chronic disease. The company manipulates neutrophil toxic behavior without destroying disease fighting function, while bringing a concentrated payload of drug to all neutrophils throughout the body with a long bioavailability, enabling healthcare institutions to treat cancer, arthritis and underlying pathologies.

Contact Information

Website
www.immunyx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 6th Avenue
  • 3rd floor
  • New York, NY 10013
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Nanotechnology, HealthTech, Life Sciences, Oncology
Corporate Office
  • 101 6th Avenue
  • 3rd floor
  • New York, NY 10013
  • United States

Immunyx Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunyx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator 21-Jun-2023 $30K Completed Startup
5. Early Stage VC 04-Mar-2023 Completed Startup
4. Accelerator/Incubator 23-Jan-2023 Completed Startup
3. Accelerator/Incubator 24-Jan-2022 Completed Startup
2. Accelerator/Incubator 15-Oct-2021 Completed Startup
1. Accelerator/Incubator 01-Jan-2021 Completed Startup
To view Immunyx’s complete valuation and funding history, request access »

Immunyx Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Immunyx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3241030-A1 Neutrophil exocytosis inhibitors Pending 15-Dec-2021
EP-4448101-A1 Neutrophil exocytosis inhibitors Pending 15-Dec-2021
US-12194034-B2 Neutrophil exocytosis inhibitors Active 15-Dec-2021
US-20240293390-A1 Neutrophil exocytosis inhibitors Active 15-Dec-2021
WO-2023112038-A1 Neutrophil exocytosis inhibitors Inactive 15-Dec-2021 A61K31/4545
To view Immunyx’s complete patent history, request access »

Immunyx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunyx Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
EIT Health Accelerator/Incubator
Hadasit Venture Capital Minority
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
Yissum Accelerator/Incubator
Endless Frontier Labs Accelerator/Incubator Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Immunyx FAQs

  • When was Immunyx founded?

    Immunyx was founded in 2021.

  • Where is Immunyx headquartered?

    Immunyx is headquartered in New York, NY.

  • What is the size of Immunyx?

    Immunyx has 6 total employees.

  • What industry is Immunyx in?

    Immunyx’s primary industry is Drug Discovery.

  • Is Immunyx a private or public company?

    Immunyx is a Private company.

  • What is Immunyx’s current revenue?

    The current revenue for Immunyx is .

  • How much funding has Immunyx raised over time?

    Immunyx has raised $30K.

  • Who are Immunyx’s investors?

    EIT Health, Hadasit, Johnson & Johnson Innovation - JLABS, Yissum, and Endless Frontier Labs are 5 of 7 investors who have invested in Immunyx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process